Needham raised the firm’s price target on Praxis Precision (PRAX) to $510 from $460 and keeps a Buy rating on the shares. The firm is citing its physician survey, which raises its 2035 ulixacaltamide revenues from about $4.4B to $4.8B and accelerates its projected ramp, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis
- Palantir upgraded, Best Buy downgraded: Wall Street’s top analyst calls
- Praxis Precision initiated with an Equal Weight at Wells Fargo
- Praxis Precision price target raised to $1,245 from $340 at H.C. Wainwright
- Praxis Precision price target raised to $554 from $353 at TD Cowen